Targeting BRAF‐Mutant Non‐Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy

Non‐small cell lung cancer (NSCLC) remains the leading cause of cancer‐related deaths globally. However, the identification of oncogenic driver alterations involved in the initiation and maintenance of NSCLC, such as epidermal growth factor receptor mutations and anaplastic lymphoma kinase transloca...

Descripción completa

Detalles Bibliográficos
Autores principales: Baik, Christina S., Myall, Nathaniel J., Wakelee, Heather A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2017
Materias:
Academia‐Pharma Intersect: Lung Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507646/
https://www.ncbi.nlm.nih.gov/pubmed/28487464
http://dx.doi.org/10.1634/theoncologist.2016-0458

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507646/
https://www.ncbi.nlm.nih.gov/pubmed/28487464
http://dx.doi.org/10.1634/theoncologist.2016-0458

Ejemplares similares